Controlled Buisness

Controlled business in insurance refers to the business that an insurance agent or broker places with the insurer that they are affiliated with. The term "controlled" implies that the agent or broker has some degree of control over the business that they place with their affiliated insurer.

Here are some key features of controlled business in insurance:

• Affiliation: Controlled business arises from the relationship between an insurance agent or broker and the insurer that they are affiliated with.

• Incentives: Agents or brokers may be incentivized to place more business with their affiliated insurer through various means such as higher commissions, bonuses, or other rewards.

• Regulation: The insurance industry is heavily regulated, and regulators are particularly concerned about controlled business because it may create conflicts of interest that could harm consumers.

• Disclosure: To address these concerns, regulators may require agents and brokers to disclose their affiliations with insurers and any incentives that they receive for placing business with a particular insurer.

For example, an insurance agent may be affiliated with an insurer and receive a higher commission for placing business with that insurer. The agent may have some degree of control over the business they place with that insurer, such as steering clients towards that insurer or offering incentives to clients to purchase policies from that insurer. Regulators may require the agent to disclose their affiliation and any incentives that they receive to ensure transparency and protect consumers.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.